The monoclonal antibody from Sanofi and AstraZeneca, called Beyfortus, is the first of its kind likely to be widely available to everyone up to 24 months of age beyond a small population of ...

Called Nirsevimab, the shot will be sold under the brand name Beyfortus. It is a ready-made antibody that can block the RSV virus from infecting cells. Technically, it's not a vaccine, but a ...